EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial

Brett King, Benjamin Ehst, Peter Foley, Pascal Reygagne, Manabu Ohyama, Jacek C Szepietowski, Zoran Popmihajlov, Francesco De Leonardis, Lauren Hippeli, Michelle Treitel, Brandon Johnson, Coryandar Gilvary und 3 weitere

British Journal of Dermatology · 17.07.2026 · 195 (2) · 211-221

DOI: 10.1093/bjd/ljag109 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, online erschienen am 30.03.2026. Verfasst von Brett King und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Physicians of Connecticut, Fairfield, CT, USA. Hauptthemen laut MEDLINE: Alopecia Areata, Protein Kinase Inhibitors, TYK2 Kinase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alopecia areata (AA) is a common, immune-mediated inflammatory disease characterized by nonscarring hair loss. Tyrosine kinase (TYK)2 mediates signalling of select proinflammatory cytokines [e.g. interleukin (IL)-12, IL-23 and type I interferons], which may play a role in the pathogenesis of AA.

Objectives

To evaluate the efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with AA.

Methods

Patients were randomized 1 : 1 : 1 to oral placebo, deucravacitinib 6 mg once daily, or deucravacitinib 6 mg twice daily. At week 24, patients randomized to placebo were rerandomized 1 : 1 to deucravacitinib 6 mg once daily or deucravacitinib 6 mg twice daily until week 52. The primary efficacy endpoint was change from baseline in Severity of Alopecia Tool (SALT) score at week 24. Secondary endpoints were proportions of patients achieving ≥ 50% reduction from baseline in SALT score (SALT 50), SALT score ≤ 20, and Alopecia Areata Investigator Global Assessment score of 0 (clear) or 1 (almost clear) with ≥ 2-point improvement from baseline at week 24. This trial was terminated following database lock at week 24, but before primary data readout, owing to a strategic decision by the sponsor and not as a result of any observed, expected or perceived efficacy or safety findings with deucravacitinib treatment. Early termination did not affect study power.

Results

In total, 94 patients received placebo (n = 31), deucravacitinib 6 mg once daily (n = 32), or deucravacitinib 6 mg twice daily (n = 31). Baseline disease characteristics were balanced across treatment groups. No meaningful difference in change from baseline in SALT score at week 24 was observed between the deucravacitinib and placebo groups [6 mg once daily: adjusted mean difference 1.5, 95% confidence interval (CI) −6.2 to 9.2, P = 0.701; 6 mg twice daily: 8.2, 95% CI 0.2–16.2, P = 0.045]. Similarly, no differences were observed for any secondary endpoint. No new safety signals were identified.

Conclusions

This trial did not meet the efficacy endpoints and TYK2 inhibition by deucravacitinib may not play a major role in hair regrowth in patients with AA. The safety of deucravacitinib in patients with AA was consistent with the known safety profile of this TYK2 inhibitor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataProtein Kinase InhibitorsTYK2 KinaseHumansFemaleDouble-Blind MethodAdultMaleTreatment OutcomeMiddle AgedAdministration, OralYoung AdultAdolescentTyrosine Kinase InhibitorsDrug Administration Schedule

Substanzen

Protein Kinase InhibitorsTYK2 KinaseTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Dermatology Physicians of Connecticut, Fairfield, CT, USA.
  • Oregon Medical Research Center, Portland, OR, USA.
  • The University of Melbourne, St. Vincent's Hospital Melbourne, and Skin Health Institute, Melbourne, VIC, Australia.
  • Centre de Santé Sabouraud, Hôpital Saint Louis, Paris, France.
  • Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Division of Dermatology, Venereology, and Clinical Immunology, Faculty of Medicine, Wrocław University of Science and Technology, Wrocław, Poland; City Clinic, Medical and Psychological Center, Wrocław, Poland.

Förderung

  • Bristol Myers Squibb

Zitieren

APA

King, B., Ehst, B., Foley, P., Reygagne, P., Ohyama, M., Szepietowski, J. C., Popmihajlov, Z., De Leonardis, F., Hippeli, L., Treitel, M., Johnson, B., Gilvary, C., Vaile, J., Daamen, C., & Passeron, T. (2026). Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial. British Journal of Dermatology, 195(2), 211-221. https://doi.org/10.1093/bjd/ljag109

Vancouver

King B, Ehst B, Foley P, Reygagne P, Ohyama M, Szepietowski JC, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial. British Journal of Dermatology. 2026;195(2):211-221. doi:10.1093/bjd/ljag109

BibTeX
@article{King2026,
  author = {King, Brett and Ehst, Benjamin and Foley, Peter and Reygagne, Pascal and Ohyama, Manabu and Szepietowski, Jacek C and Popmihajlov, Zoran and De Leonardis, Francesco and Hippeli, Lauren and Treitel, Michelle and Johnson, Brandon and Gilvary, Coryandar and Vaile, John and Daamen, Carolin and Passeron, Thierry},
  title = {Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial},
  journal = {British Journal of Dermatology},
  year = {2026},
  volume = {195},
  number = {2},
  pages = {211--221},
  doi = {10.1093/bjd/ljag109}
}
Kostenlos starten →